Lastly, SGLT2 inhibitors have also been found to reduce the incidence of obstructive sleep apnea and have favorable impact on risk factors for cardiovascular outcomes in patients with T2D and ASCVD [64, 65]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.